PHAGEVAX, INC. Information

The next logical step, will be challenge in non-human Primates? Approximately 100 million Americans have contracted Coronavirus (components) either through vaccination or natural infection. Reminder, that reports regarding the Pfizer Paxlovid antiviral pill, seems to allow regeneration/less kill rate of the resident CoV (soon after completing the course of 10 pills), which is very disappointing. Only 20 million courses were purchased. It takes 8 months to make a pill, according to reporting. Generally people do not like needles (better compliance is needed); delivery in the US Mail; stable at room temperature; team is working on cGMP; may prove less shedding; may prove fewer re-infections; deserves T Cells distribution in various important tissues analysis; rapid turnaround times, as virulent types are discovered; moduler & flexibility, built in. The same vaccine platform can serve as prevention vs many different diseases; simply exchange the antigens/epitopes. Today we face the largest pandemic threats in modern history. The World Health Organization (WHO) has deemed the H1N1 Swine Flu an unstoppable worldwide virus. Some experts warn that viral mixes could trigger an even more deadly strain ( source ). With these prospects, what can be done? What if there was a way not only to produce vaccine in a quarter of the time that most large vaccine labs manufacture vaccines, but also to do it with a mobile platform easily transported to the hardest hit pandemic hotspots? PhageVax, Inc. has that solution. As noted in the recent Centers for Disease Control and Prevention community planning guidance1, the only intervention that can reasonably be expected to control an influenza pandemic is vaccination of a large fraction of the population with a strain-matched vaccine. Planners and modelers commonly assume that such a vaccine intervention would be similar to recent vaccination interventions for seasonal influenza, employing egg-based vaccine production technology. Thus analyses assume that pandemic influenza vaccine ...